Rezolute EBITDA 2011-2026 | RZLT

Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.^[1]

EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.

EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.

However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.

Annual EBITDA Rezolute

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-79.9 M	-70.4 M	-56 M	-41.8 M	-22.9 M	-20.5 M	-25.8 M	-25.3 M	-19.2 M	-14.2 M	-10.6 M	-5.16 M	-6.11 M	-45.5 K	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
-45.5 K	-79.9 M	-28.4 M

Quarterly EBITDA Rezolute

2025-Q4	2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-19.8 M	-	-	-	-16.9 M	-	-	-	-15.9 M	-	-	-14.4 M	-10.2 M	-24.6 M	-10.8 M	-12.1 M	-7.64 M	-19.8 M	-5.48 M	-7.15 M	-3.62 M	-7.15 M	-3.62 M	-6.72 M	-5.17 M	-6.71 M	-5.17 M	-3.15 M	-2.54 M	-3.12 M	-2.3 M	-5.48 M	-6.45 M	-5.22 M	-6.45 M	-4.61 M	-3.56 M	-4.61 M	-3.56 M	-3.92 M	-3.23 M	-3.92 M	-3.23 M	-3.04 M	-2.21 M	-3.01 M	-2.21 M	-649 K	-700 K	-648 K	-700 K	-500 K	-543 K	-	-94.6 K	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
-94.6 K	-24.6 M	-6.14 M

References

Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.

EBITDA of other stocks in the Biotechnology industry

Issuer	EBITDA	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	-508 M	-	2.43 %	$ 254 M	Germany
AbCellera Biologics ABCL	-199 M	$ 3.56	2.01 %	$ 1.06 B	Canada
Acorda Therapeutics ACOR	-233 M	-	-24.86 %	$ 820 K	USA
Acasti Pharma ACST	-16.7 M	-	4.01 %	$ 150 M	Canada
Advaxis ADXS	-35.9 M	-	-9.65 %	$ 45.9 M	USA
I-Mab IMAB	13.8 M	-	-	$ 866 M	China
Aeglea BioTherapeutics AGLE	-242 M	-	-	$ 1.01 B	USA
AgeX Therapeutics AGE	-9.76 M	-	-10.17 %	$ 12.2 K	USA
Aptorum Group Limited APM	1.19 M	$ 0.79	-0.79 %	$ 4.31 M	China
Alexion Pharmaceuticals, Inc. ALXN	3.11 B	-	-	$ 40.3 B	USA
Biophytis SA BPTS	-26.8 M	-	-13.47 %	$ 169 M	France
Albireo Pharma ALBO	-123 M	-	-0.23 %	$ 916 M	USA
Aileron Therapeutics ALRN	-65 M	-	10.36 %	$ 9.8 M	USA
argenx SE ARGX	-349 M	$ 703.3	0.41 %	$ 25 B	Niderland
EyeGate Pharmaceuticals, Inc. EYEG	-8.18 M	-	-1.52 %	$ 24.7 M	USA
Ascendis Pharma A/S ASND	-452 M	$ 231.03	2.23 %	$ 5 B	Danmark
ADC Therapeutics SA ADCT	-262 M	$ 4.22	2.18 %	$ 105 M	Schweiz
Alterity Therapeutics Limited ATHE	-17.3 M	$ 3.61	0.28 %	$ 8.69 B	Australia
Midatech Pharma plc MTP	-7 M	-	-18.52 %	$ 27.3 M	Britain
Adverum Biotechnologies ADVM	-136 M	-	-	$ 86.2 M	USA
Applied Genetic Technologies Corporation AGTC	-16.2 M	-	-	$ 26.5 M	USA
Applied Molecular Transport AMTI	-124 M	-	-	$ 10.1 M	USA
Arcturus Therapeutics Holdings ARCT	-73.2 M	$ 6.63	-0.75 %	$ 182 M	Israel
Институт стволовых клеток человека ISKJ	220 M	-	-	-	Russia
Akero Therapeutics AKRO	-285 M	-	-	$ 3.67 B	USA
Athersys ATHX	-85.6 M	-	3.77 %	$ 22.4 M	USA
Akouos AKUS	-84.3 M	-	0.23 %	$ 488 M	USA
Acer Therapeutics ACER	-24.5 M	-	2.71 %	$ 14 M	USA
ARCA biopharma ABIO	-88.1 M	-	1052.0 %	$ 415 M	USA
Allena Pharmaceuticals ALNA	-47.3 M	-	3.16 %	$ 1.9 M	USA
Aeterna Zentaris AEZS	-8.67 M	-	5.93 %	$ 314 M	Canada
AlloVir ALVR	-200 M	-	4.14 %	$ 49.1 M	USA
Anika Therapeutics ANIK	-81.2 M	$ 14.36	1.13 %	$ 210 M	USA
Aptinyx APTX	-62.4 M	-	-39.0 %	$ 4.57 M	USA
BioNTech SE BNTX	15.3 B	$ 90.54	-0.71 %	$ 27.2 B	Germany
Aptose Biosciences APTO	32 K	-	-45.71 %	$ 1.2 M	Canada
Burford Capital Limited BUR	242 M	$ 8.05	1.64 %	$ 1.31 B	Britain
AVEO Pharmaceuticals AVEO	-49.5 M	-	-	$ 521 M	USA
Atea Pharmaceuticals AVIR	-180 M	$ 6.05	-0.82 %	$ 493 M	USA
Ayala Pharmaceuticals AYLA	-37.3 M	-	-	$ 7.46 M	Israel
Aytu BioScience AYTU	-2.45 M	$ 2.64	3.94 %	$ 16.6 M	USA
Avenue Therapeutics ATXI	-11.3 M	-	-52.27 %	$ 4.45 M	USA
BioCardia BCDA	-11.6 M	$ 1.27	0.79 %	$ 26.9 M	USA
Autolus Therapeutics plc AUTL	-234 M	$ 1.51	4.86 %	$ 385 M	Britain
Athira Pharma ATHA	-99.9 M	-	-	$ 269 M	USA
Can-Fite BioPharma Ltd. CANF	-10.1 M	$ 3.58	-0.56 %	$ 7.79 B	Israel
CureVac N.V. CVAC	-412 M	-	-	$ 867 M	Germany
Aravive ARAV	-70 M	-	-13.39 %	$ 1.45 M	USA
AstraZeneca PLC AZN	1.06 B	-	-	$ 96.9 B	Britain
Actinium Pharmaceuticals ATNM	-41.9 M	$ 1.11	-	$ 33.4 M	USA